On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADJUVANT BR.31 Phase 3 trial, sponsored by the Canadian Cancer Trials Group. The data showed that Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of disease-free survival versus placebo in early-stage non-small cell lung cancer (NSCLC) after complete tumor resection in patients whose tumors express PD-L1 on 25% or more tumor cells. “We are disappointed in the ADJUVANT BR.31 results,” said Susan Galbraith, executive vice president of oncology research and development at AstraZeneca. The safety profile for Imfinzi was consistent with its known safety profile, and no new safety concerns were reported. Imfinzi is the only approved immunotherapy and the global standard of ...